JP2020533273A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533273A5
JP2020533273A5 JP2020503686A JP2020503686A JP2020533273A5 JP 2020533273 A5 JP2020533273 A5 JP 2020533273A5 JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020533273 A5 JP2020533273 A5 JP 2020533273A5
Authority
JP
Japan
Prior art keywords
polypeptide
tmmp
amino acid
mutant
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020503686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/049756 external-priority patent/WO2019051091A1/en
Publication of JP2020533273A publication Critical patent/JP2020533273A/ja
Publication of JP2020533273A5 publication Critical patent/JP2020533273A5/ja
Pending legal-status Critical Current

Links

JP2020503686A 2017-09-07 2018-09-06 多量体t細胞調節ポリペプチドおよびその使用方法 Pending JP2020533273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555499P 2017-09-07 2017-09-07
US62/555,499 2017-09-07
PCT/US2018/049756 WO2019051091A1 (en) 2017-09-07 2018-09-06 T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

Publications (2)

Publication Number Publication Date
JP2020533273A JP2020533273A (ja) 2020-11-19
JP2020533273A5 true JP2020533273A5 (https=) 2021-10-28

Family

ID=65634643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020503686A Pending JP2020533273A (ja) 2017-09-07 2018-09-06 多量体t細胞調節ポリペプチドおよびその使用方法

Country Status (12)

Country Link
US (4) US20200148744A1 (https=)
EP (1) EP3678691A4 (https=)
JP (1) JP2020533273A (https=)
KR (1) KR20200040860A (https=)
CN (1) CN111050793A (https=)
AU (1) AU2018328280B2 (https=)
BR (1) BR112020004535A2 (https=)
CA (1) CA3070484A1 (https=)
EA (1) EA202090471A1 (https=)
IL (2) IL272085B2 (https=)
MX (1) MX2020002596A (https=)
WO (1) WO2019051091A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ,インコーポレーテッド コンジュゲーション部位を有するt細胞調節多量体ポリペプチド及びその使用方法
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體t細胞調節多肽及其使用方法
EP3719033A1 (en) 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ, インコーポレイテッド 多量体t細胞調節性ポリペプチド及びその使用方法
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
KR102440962B1 (ko) * 2020-03-18 2022-09-07 ㈜지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN111592580A (zh) * 2020-05-08 2020-08-28 中国药科大学 一种具有免疫检查点ctla-4抑制活性的多肽及其应用
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2021230638A1 (en) * 2020-05-12 2021-11-18 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL299834A (en) * 2020-07-14 2023-03-01 Cue Biopharma Inc with binding sites and methods for using them T - cellular modulatory polypeptides
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
JP2025508958A (ja) 2022-03-01 2025-04-10 クロスリンク セラピューティクス インク. 抗癌剤としての免疫細胞機能のatp依存性アゴニスト
AU2024268752A1 (en) * 2023-05-11 2026-01-08 Immudex Aps Mhc class i molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
SG11201605632SA (en) * 2014-01-21 2016-08-30 Einstein Coll Med Cellular platform for rapid and comprehensive t-cell immunomonitoring
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
JP2020533273A5 (https=)
Korman et al. The foundations of immune checkpoint blockade and the ipilimumab approval decennial
JP2022534846A5 (https=)
Triebel LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination
Touloukian et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
CN115103852B (zh) Prame tcr受体和其用途
KR102436129B1 (ko) T 세포 수용체 및 이의 용도
JP6722189B2 (ja) 単量体Fcドメイン
Tutt et al. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
KR20220066075A (ko) T-세포 조절 폴리펩타이드 및 이의 사용 방법
JP2022515331A5 (https=)
IL272085B2 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
US20160199479A1 (en) T cell receptors
JP2022548472A5 (https=)
JP2021500855A (ja) 抗原提示ポリペプチドおよびその使用方法
JP2018524326A5 (https=)
CN110088126A (zh) Icos配体变体免疫调节蛋白及其用途
JP2024512470A (ja) T細胞調節ポリペプチド及びその使用方法
JP2022515331A (ja) 多量体t細胞調節ポリペプチド及びその使用方法
O’Herrin et al. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide
CA3149583A1 (en) Chimeric proteins in autoimmunity
WO2020132366A4 (en) T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
US20240368246A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023532278A5 (https=)
CN109562171B (zh) MHC Ia类开放型构象异构体